Giuseppe MichieliMar 28, 2024

A Phase 2 Clinical Trial to Evaluate the #Safety, Reactogenicity, and #Immunogenicity of Different Prime-Boost #Vaccination Schedules of '13 & '17 #H7N9 Inactivated #Influenza Virus Vaccines Administered with & without #AS03 Adjuvant in Healthy US Adults, Clin Infect Dis.: https://doi.org/10.1093/cid/ciae173

Administering adjuvant with 2nd H7N9 IIV dose & extending boost interval to 4 mos resulted in higher peak Ab responses. These observations can inform strategic approaches for pandemic preparedness.

A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults

AbstractIntroduction. A surge of human influenza A(H7N9) cases began in 2016 in China due to an antigenically distinct lineage. Data are needed about the s

OUP Academic
Giuseppe MichieliDec 18, 2023
#Immunogenicity and safety of varying dosages of a fifth-wave #influenza A/ #H7N9 inactivated #vaccine given with and without #AS03 adjuvant in healthy adults https://pubmed.ncbi.nlm.nih.gov/38105137/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1LGAx__djGAJ9poBzWGqPtjEbBDtz4ipSRRPUplmgHEyyF_Ihj&fc=None&ff=20231218031744&v=2.18.0
Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults - PubMed

AS03 adjuvant improved the immune responses to an inactivated fifth-wave H7N9 influenza vaccine, particularly in younger adults, but invoked lower responses to drifted H7N9 strains. These findings may inform future influenza pandemic preparedness strategies.

PubMed
Giuseppe MichieliSep 14, 2023
[Articles] #Efficacy of a #bivalent (D614   B.1.351) #SARS-CoV-2 recombinant protein #vaccine with #AS03 #adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00263-1/fulltext?rss=yes #research #covid19